文献速递冠心病血脂与心血管预防

糖尿病冠心病患者常规应用血流储备分数的临床价值

Usefulness of Routine Fractional Flow Reserve for Clinical Management of Coronary Artery Disease in Patients With Diabetes.
PubMed 文献 · JAMA Cardiol · 2020-01-01

本研究基于PRIME-FFR研究(POST-IT与R3F两个前瞻性多中心注册研究的合并数据),纳入1983例冠状动脉造影显示临界病变的患者(其中701例糖尿病),评估整合FFR对糖尿病患者治疗决策及1年MACE的影响。

要点

  • 糖尿病患者FFR重分类率与无糖尿病者相似,但由药物治疗改为血运重建更常见。
  • FFR指导的推迟血运重建在糖尿病患者中1年MACE风险低于血运重建者。
  • 胰岛素治疗状态与结局无关联,忽视FFR者MACE率最高。

核心结论

  • 常规整合FFR管理糖尿病患者的冠心病可能与较高的治疗重分类率相关。
  • FFR指导的管理策略(包括推迟血运重建)可能对糖尿病患者有用。

研究设计与样本

  • 横断面研究,数据来自PRIME-FFR研究(POST-IT与R3F两个前瞻性多中心注册研究的合并)。
  • 纳入1983例造影显示临界病变的患者,其中701例有糖尿病;平均年龄65岁(SD 10),男性1503例(77%)。
  • FFR用于每例患者1.4处病变,58.2%的病变位于左前降支;平均狭窄56%(SD 11%),平均FFR 0.81(SD 0.01)。
  • 主要终点为1年全因死亡、心肌梗死或非计划血运重建(MACE)。

主要发现

  • 胰岛素治疗状态与结局无关联。
  • 忽视FFR的患者(占6.6%)无论糖尿病状态如何,MACE率最高。

临床怎么用

  • 对糖尿病合并临界病变的患者,可常规应用FFR指导治疗决策。
  • FFR指导的推迟血运重建在糖尿病患者中可能是安全的,与较低的1年MACE风险相关。
  • 应避免忽视FFR结果,因其与最高的MACE率相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Approximately one-third of patients considered for coronary revascularization have diabetes, which is a major determinant of clinical outcomes, often influencing the choice of the revascularization strategy. The usefulness of fractional flow reserve (FFR) to guide treatment in this population is understudied and has been questioned. OBJECTIVE: To evaluate the usefulness and rate of major adverse cardiovascular events (MACE) of integrating FFR in management decisions for patients with diabetes who undergo coronary angiography. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the PRIME-FFR study derived from the merger of the POST-IT study (Portuguese Study on the Evaluation of FFR-Guided Treatment of Coronary Disease [March 2012-November 2013]) and R3F study (French Study of FFR Integrated Multicenter Registries Implementation of FFR in Routine Practice [October 2008-June 2010]), 2 prospective multicenter registries that shared a common design. A population of all-comers for whom angiography disclosed ambiguous lesions was analyzed for rates, patterns, and outcomes associated with management reclassification, including revascularization deferral, in patients with vs without diabetes. Data analysis was performed from June to August 2018. MAIN OUTCOMES AND MEASURES: Death from any cause, myocardial infarction, or unplanned revascularization (MACE) at 1 year. RESULTS: Among 1983 patients (1503 [77%] male; mean [SD] age, 65 [10] years), 701 had diabetes, and FFR was performed for 1.4 lesions per patient (58.2% of lesions in the left anterior descending artery; mean [SD] stenosis, 56% [11%]; mean [SD] FFR, 0.81 [0.01]). Reclassification by FFR was high and similar in patients with and without diabetes (41.2% vs 37.5%, P = .13), but reclassification from medical treatment to revascularization was more frequent in the former (142 of 342 [41.5%] vs 230 of 730 [31.5%], P = .001). There was no statistical difference between the 1-year rates of MACE in reclassified (9.7%) and nonreclassified patients (12.0%) (P = .37). Among patients with diabetes, FFR-based deferral identified patients with a lower risk of MACE at 12 months (25 of 296 [8.4%]) compared with those undergoing revascularization (47 of 257 [13.1%]) (P = .04), and the rate was of the same magnitude of the observed rate among deferred patients without diabetes (7.9%, P = .87). Status of insulin treatment had no association with outcomes. Patients (6.6% of the population) in whom FFR was disregarded had the highest MACE rates regardless of diabetes status. CONCLUSIONS AND RELEVANCE: Routine integration of FFR for the management of coronary artery disease in patients with diabetes may be associated with a high rate of treatment reclassification. Management strategies guided by FFR, including revascularization deferral, may be useful for patients with diabetes.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Van Belle E, Cosenza A, Baptista SB, et al. Usefulness of Routine Fractional Flow Reserve for Clinical Management of Coronary Artery Disease in Patients With Diabetes. JAMA Cardiol. 2020. PMID: 31913433. doi:10.1001/jamacardio.2019.5097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。